副腎皮質ステロイド阻害薬市場：薬剤、治療タイプ、流通チャネル、エンドユーザー別-2025-2030年の世界予測

副腎皮質ステロイド阻害薬市場は、2023年に24億9,000万米ドルと評価され、2024年には28億米ドルに達すると予測され、CAGR 12.75％で成長し、2030年には57億8,000万米ドルになると予測されています。

副腎皮質ステロイド阻害薬は、副腎で産生されるコルチコステロイドの合成と作用を阻害するように設計された医薬品であり、主にクッシング症候群や副腎皮質ホルモン分泌過多症のような病態を対象としています。これらの阻害剤の必要性は、ホルモンレベルのバランスを整え、コルチゾールの過剰産生に伴う症状を緩和する能力から生じる。その用途は内分泌学にまで及び、ホルモンバランスの乱れを管理するために極めて重要であり、標準的な治療法に反応しない重度の難治性疾患を治療するために極めて重要です。最終用途の範囲には、病院、専門クリニック、臨床研究機関などの医療部門が主に含まれます。市場の洞察によると、副腎関連疾患の有病率の増加と、認知度や診断能力の向上が、市場の力強い成長軌道を牽引しています。さらに、薬理学の進歩が研究を刺激し、より強力で標的を絞った阻害剤の開発につながっています。ヘルスケアのインフラが拡大し、認知度が高まっている新興市場にはチャンスがあふれています。このチャンスを活かそうとする企業にとっては、徐放性製剤など新規の送達メカニズムの開発に戦略的に注力することで、競合情勢の中で製品の差別化を図ることができます。しかし、厳しい規制環境、高い薬剤開発コスト、患者のコンプライアンスを阻害しかねない潜在的な副作用などにより、市場は限界に直面しています。副腎疾患の複雑な性質は、正確な診断と治療効果における課題も示唆しています。個別化医療の革新、遺伝学的知見の活用による阻害剤プロファイルの調整、バイオテクノロジー企業と製薬企業の協力関係の強化は、事業の大きな成長を促進する可能性があります。市場は成長志向ではあるが慎重な傾向にあり、規制状況の変化を予測し、迅速に適応し、最先端の研究と患者中心のソリューションに投資する企業が最もチャンスをつかみやすいです。こうした障壁を乗り越えることができる企業は、競合優位性を獲得し、進化する治療情勢に貢献することができると思われます。

市場力学：急速に進化する副腎皮質ステロイド阻害薬市場の主要市場インサイトを公開

副腎皮質ステロイド阻害薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 内分泌疾患の治療に対する副腎皮質ステロイド阻害薬のニーズの高まり
  • 副腎皮質ステロイド阻害薬ベースの医薬品に対する政府承認の増加
• 市場抑制要因
  • 副腎皮質ステロイド阻害薬に関する認知度の低さとコストの高さ
• 市場機会
  • 副腎皮質ステロイド阻害薬の研究開発への多額の投資
  • 洗練された医療施設の存在感の高まりと医薬品分野の進歩
• 市場の課題
  • 副腎皮質ステロイド阻害薬ベースの医薬品の副作用に関する懸念

ポーターのファイブフォース：副腎皮質ステロイド阻害薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、副腎皮質ステロイド阻害薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：副腎皮質ステロイド阻害薬市場における外部からの影響の把握

外部マクロ環境要因は、副腎皮質ステロイド阻害薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析副腎皮質ステロイド阻害薬市場における競合情勢の把握

副腎皮質ステロイド阻害薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス副腎皮質ステロイド阻害薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、副腎皮質ステロイド阻害薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨副腎皮質ステロイド阻害薬市場における成功への道筋を描く

副腎皮質ステロイド阻害薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 内分泌疾患の治療における副腎皮質ステロイド阻害薬の必要性の高まり
    • 副腎皮質ステロイド阻害剤ベースの薬剤に対する政府承認の増加
  • 抑制要因
    • 副腎皮質ステロイド阻害薬に関連する認知度が低く、コストが高い
  • 機会
    • 副腎皮質ステロイド阻害薬の研究開発への多額の投資
    • 洗練された医療施設の増加と製薬分野の進歩
  • 課題
    • 副腎皮質ステロイド阻害薬をベースとした薬剤の副作用に関する懸念
• 市場セグメンテーション分析
  • 医薬品：疾患の長期治療選択肢としてオシロドロスタット薬の利用が急増
  • 治療の種類：クッシング症候群の治療における副腎皮質ステロイド阻害薬の使用増加
  • 配信チャネル：副腎皮質ステロイド阻害薬の進化するオンライン配信チャネル
  • エンドユーザー：専門センターでの副腎皮質ステロイド阻害薬の大幅な採用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 副腎皮質ステロイド阻害薬市場薬物別

• アミノグルテチミド
• レボケトコナゾール
• メチラポン
• オシロドロスタット

第7章 副腎皮質ステロイド阻害薬市場治療の種類別

• 乳がん
• クッシング症候群
• 前立腺がん

第8章 副腎皮質ステロイド阻害薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 副腎皮質ステロイド阻害薬市場：エンドユーザー別

• 病院
• 専門センター

第10章 南北アメリカの副腎皮質ステロイド阻害薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の副腎皮質ステロイド阻害薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの副腎皮質ステロイド阻害薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • CoherusとJunshi Biosciencesが、再発性または転移性鼻咽頭がん（NPC）のすべての治療ラインでLOQTORZI（toripalimab-tpzi）のFDA承認を発表
  • 米国FDA、BRCA陽性転移性去勢抵抗性前立腺がん患者の治療として二重作用錠剤AKEEGA（ニラパリブとアビラテロン酢酸塩）を承認
  • モデナ社とメルク社、KEYTRUDA（R）（ペムブロリズマブ）との併用による治験中のパーソナライズmRNAがんワクチンmRNA-4157/V940が第2b相KEYNOTE-942試験で主要有効性エンドポイントを達成したことを発表
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adooq Bioscience LLC
• Cayman Chemical Company
• Crinetics Pharmaceuticals, Inc.
• Eli Lilly and Company
• Enzo Life Sciences, Inc.
• Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
• HRA Pharma Rare Diseases SAS by Perrigo Company plc
• MedChemExpress
• Merck KGaA
• Novartis AG
• Orphagen Pharmaceuticals
• Pfizer Inc.
• Sparrow Pharmaceuticals Inc.
• Steris Healthcare PVT Ltd
• Tocris Bioscience by Bio-Techne Corporation
• Xeris Biopharma Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET RESEARCH PROCESS
• FIGURE 2. ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ADRENAL CORTICOSTEROID INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ADRENAL CORTICOSTEROID INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ADRENAL CORTICOSTEROID INHIBITORS MARKET DYNAMICS
• TABLE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 59. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 63. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 132. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 148. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 152. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. ADRENAL CORTICOSTEROID INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. ADRENAL CORTICOSTEROID INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

The Adrenal Corticosteroid Inhibitors Market was valued at USD 2.49 billion in 2023, expected to reach USD 2.80 billion in 2024, and is projected to grow at a CAGR of 12.75%, to USD 5.78 billion by 2030.

Adrenal Corticosteroid Inhibitors are pharmaceutical agents designed to block the synthesis and effects of corticosteroids produced in the adrenal gland, primarily aimed towards conditions like Cushing's syndrome or hypercortisolism. The necessity of these inhibitors arises from their ability to balance hormone levels and alleviate symptoms associated with excessive cortisol production. Their application extends to endocrinology, being crucial for managing hormonal imbalances, and they are pivotal for treating severe refractory conditions that do not respond to standard therapies. The end-use scope predominantly includes health sectors such as hospitals, specialty clinics, and clinical research institutions. Market insights reveal a robust growth trajectory driven by an increase in the prevalence of adrenal-related disorders coupled with greater awareness and diagnostic capabilities. Furthermore, advancements in pharmacology have stimulated research, leading to the development of more potent and targeted inhibitors. Opportunities are abound in emerging markets where healthcare infrastructure is expanding, and awareness is rising. For companies looking to capitalize, a strategic focus on the development of novel delivery mechanisms, such as extended-release formulations, can differentiate offerings in a competitive landscape. However, the market faces limitations due to stringent regulatory environments, high costs of drug development, and potential side effects, which can obstruct patient compliance. The complex nature of adrenal disorders also suggests challenges in accurate diagnosis and treatment efficacy. Innovating in personalized medicine, leveraging genetic insights to tailor inhibitor profiles, and enhancing collaboration between biotech and pharmaceutical companies can foster significant business growth. The market tends towards a growth-oriented but cautious landscape, with opportunities best captured by those who anticipate regulatory changes, adapt promptly, and invest in cutting-edge research and patient-centric solutions. Companies able to navigate through these barriers will likely achieve competitive advantage and contribute to the evolving therapeutic landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adrenal Corticosteroid Inhibitors Market

The Adrenal Corticosteroid Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
  • Rising government approvals for adrenal corticosteroid inhibitors-based drugs
• Market Restraints
  • Limited awareness and high cost associated with adrenal corticosteroid inhibitors
• Market Opportunities
  • Significant investments in research and development of adrenal corticosteroid inhibitors
  • Growing presence of refined medical facilities and advances in pharmaceutical sector
• Market Challenges
  • Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs

Porter's Five Forces: A Strategic Tool for Navigating the Adrenal Corticosteroid Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adrenal Corticosteroid Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adrenal Corticosteroid Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adrenal Corticosteroid Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adrenal Corticosteroid Inhibitors Market

A detailed market share analysis in the Adrenal Corticosteroid Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adrenal Corticosteroid Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adrenal Corticosteroid Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adrenal Corticosteroid Inhibitors Market

A strategic analysis of the Adrenal Corticosteroid Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adrenal Corticosteroid Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adooq Bioscience LLC, Cayman Chemical Company, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Enzo Life Sciences, Inc., Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., HRA Pharma Rare Diseases SAS by Perrigo Company plc, MedChemExpress, Merck KGaA, Novartis AG, Orphagen Pharmaceuticals, Pfizer Inc., Sparrow Pharmaceuticals Inc., Steris Healthcare PVT Ltd, Tocris Bioscience by Bio-Techne Corporation, and Xeris Biopharma Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Adrenal Corticosteroid Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Aminoglutethimide, Levoketoconazole, Metyrapone, and Osilodrostat.
• Based on Treatment Type, market is studied across Breast Cancer, Cushing's Syndrome, and Prostate Cancer.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on End-user, market is studied across Hospitals and Speciality Centres.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
    • 5.1.1.2. Rising government approvals for adrenal corticosteroid inhibitors-based drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Limited awareness and high cost associated with adrenal corticosteroid inhibitors
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant investments in research and development of adrenal corticosteroid inhibitors
    • 5.1.3.2. Growing presence of refined medical facilities and advances in pharmaceutical sector
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
  • 5.2.2. Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome
  • 5.2.3. Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
  • 5.2.4. End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Adrenal Corticosteroid Inhibitors Market, by Drug

• 6.1. Introduction
• 6.2. Aminoglutethimide
• 6.3. Levoketoconazole
• 6.4. Metyrapone
• 6.5. Osilodrostat

7. Adrenal Corticosteroid Inhibitors Market, by Treatment Type

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Cushing's Syndrome
• 7.4. Prostate Cancer

8. Adrenal Corticosteroid Inhibitors Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Adrenal Corticosteroid Inhibitors Market, by End-user

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Speciality Centres

10. Americas Adrenal Corticosteroid Inhibitors Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Adrenal Corticosteroid Inhibitors Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Adrenal Corticosteroid Inhibitors Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
  • 13.3.2. U.S. FDA Approves AKEEGA (Niraparib and Abiraterone Acetate), the Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
  • 13.3.3. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adooq Bioscience LLC
• 3. Cayman Chemical Company
• 4. Crinetics Pharmaceuticals, Inc.
• 5. Eli Lilly and Company
• 6. Enzo Life Sciences, Inc.
• 7. Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
• 8. HRA Pharma Rare Diseases SAS by Perrigo Company plc
• 9. MedChemExpress
• 10. Merck KGaA
• 11. Novartis AG
• 12. Orphagen Pharmaceuticals
• 13. Pfizer Inc.
• 14. Sparrow Pharmaceuticals Inc.
• 15. Steris Healthcare PVT Ltd
• 16. Tocris Bioscience by Bio-Techne Corporation
• 17. Xeris Biopharma Holdings, Inc.